JDRF & the Type 1 Diabetes (T1D) Community JDRF Patient - - PDF document

jdrf the type 1 diabetes t1d community
SMART_READER_LITE
LIVE PREVIEW

JDRF & the Type 1 Diabetes (T1D) Community JDRF Patient - - PDF document

JDRF & the Type 1 Diabetes (T1D) Community JDRF Patient organization Volunteers with personal connection to T1D comprise board & research committee Largest non-profit funder Largest non profit funder of T1D research


slide-1
SLIDE 1

1

JDRF & the Type 1 Diabetes (T1D) Community

JDRF

  • Patient organization
  • Volunteers with personal

connection to T1D comprise board & research committee

  • Largest non-profit funder

Largest non profit funder

  • f T1D research

worldwide

  • Mission: accelerate

breakthroughs to cure, treat, prevent T1D

slide-2
SLIDE 2

2

  • Life-threatening autoimmune disease requiring intensive

insulin therapy and monitoring

About Type 1 Diabetes (T1D)

py g

  • Intensive insulin therapy provides glycemic control
  • Adequate glycemic control delays or prevents onset of long

term, serious complications (e.g., kidney failure, blindness, heart attacks, and stroke)

  • Intensive insulin therapy creates risk and fear of hypoglycemia

py yp g y

3

Average Current HbA1c by Age

9

How are We Doing? Most with T1D are Not at Goal

7.5 8 8.5 Mean HbA1c 6yo 17yo

4 4

7 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 M Age, years* 30yo

*≤2 years old and ≥80 years old are pooled

HBA1c Goal

slide-3
SLIDE 3

3

Challenges of Hypoglycemia & Diabetic Ketoacidosis (DKA) in Adults with T1D

Severe Hypoglycemia Resulting in Seizure or Loss of Consciousness in Past 12 Months

  • Severe

Hypoglycemia is

Diabetic Ketoacidosis Requiring Overnight Hospitalization in Past 12 Months

relatively common, regardless of A1c

  • DKA risk

increases

5

p

dramatically with A1c, but persists at all A1c levels

  • Severe hypoglycemia can cause seizures, comas, deaths
  • Mild

d d t h l i

Hypoglycemia is Problematic in All its Forms

  • Mild and moderate hypoglycemia can cause
  • Disorientation
  • Falls, accidents
  • Work, life disruptions
  • And can lead to severe episodes
  • Fear of hypoglycemia can cause poor glucose control

6

slide-4
SLIDE 4

4

  • Studies report that

Nocturnal Hypoglycemia is Especially Dangerous for Individuals with T1D

55% of severe hypoglycemia episodes

  • ccur during sleep
  • An estimated 2-4% of

deaths in individuals with T1D have been attributed to severe hypoglycemia

7

Buckingham B, Block J, Burdick J, et al. Response to nocturnal alarms using a real-time glucose sensor. Diabetes Technol Ther. 2005;7:440– 447; Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 2003; 26:1902-1912.

12-MONTH FREQUENCY OF SEVERE HYPOGLYCEMIA* BY AGE

Rates of Hypoglycemia are Too High

7% 9% 11% 13% 16% 6% 8% 10% 12% 14% 16% 18% 20% 5% 4% 5% 0% 2% 4% <6 6-<13 13-<18 18-<26 26-<31 31-<50 50-<65 ≥65 Age (years)

8

2014 T1D Exchange registry data on file through August 2014 N=14,163 (>70 sites in USA) https://t1dexchange.org/

* 1 or more events in 12 months; Severe hypoglycemia = seizure or loss of consciousness.

slide-5
SLIDE 5

5

  • Decision makers are not always aware of or know how to value
  • ther T1D outcomes such as hypoglycemia

Key Decision Makers are Focused Narrowly on HbA1c

  • ther T1D outcomes such as hypoglycemia
  • Impacts decision making related to diabetes therapies
  • Impacts access to diabetes therapies
  • Additionally, healthcare provider payments are increasingly

tied to outcomes (e.g., HbA1c), which impacts clinical practice

9

  • Collaborative initiative of JDRF, patients, clinicians, researchers

R i i h h HbA1 i

T1D Outcomes Program

  • Recognition that more than HbA1c matters to patients
  • Agree on definition and measurement of outcomes like

hypoglycemia to:

  • Appreciate all types of hypoglycemia as meaningful
  • Ensure outcomes are measured as endpoints in clinical trials
  • Gain agreement from regulators on use of outcomes in
  • Gain agreement from regulators on use of outcomes in

regulatory decision-making

  • Expand diabetes outcomes accepted by US payers

10

slide-6
SLIDE 6

6

How Congress Can Help

  • Continuous Glucose

Monitors, an important tool for reducing hypoglycemia, are not covered by Medicare

T1D & HYPOGLYCEMIA

are not covered by Medicare

  • 95% of commercial payers

provide CGM coverage

  • Recommended by all diabetes

clinical guidelines

  • Cosponsor Medicare CGM

Access Act (S 804 & HR 1427) to address gap

11